News archive

As Novartis expands its manufacturing capabilities, our new Carlsbad facility will help deliver time-sensitive cancer treatments to patients, meeting future demand.

Learn how community-driven partnerships are helping to break down barriers and support access to health care.

Radioligand therapies harness the power of radioisotopes to target cancer with precision. For Matt Baca, delivering a dose in a three-to-five-day window is all in a day’s work.

At this award-winning two-day event, more than 150 high school students gathered to acquire professional skills that will empower them to lead successful futures.

Creating truly equal care for patients with advanced prostate cancer begins by learning from those often overlooked and help them feel seen, heard, and understood.

In this interview, Katie shares the experiences that have shaped her leadership philosophy, her vision for pioneering new approaches in patient support, and why she believes the future of healthcare lies in combining technological innovation with genuine connection. 

High Lp(a) is an inherited condition that can independently increase the risk of heart disease^1,2,3. Read on.

How do women’s feelings about their breasts impact breast health? We asked 3000 women in the first ever Novartis Breast Health & Experience Index.

In the complex journey of advanced prostate cancer, care doesn’t just happen in the clinic. It includes everyday emotional and practical challenges patients and families face. Social workers help bridge these gaps.

These scientifically advanced technologies may help transform millions of patients’ lives

Twenty-five years ago, Novartis pioneered a paradigm shift in cancer care with the introduction of the first tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML), transforming it from a deadly disease into a chronic condition for most patients. This breakthrough helped lay the foundation for targeted therapies in oncology and continues to shape the future of CML treatment today.